Silexion Therapeutics (NASDAQ: SLXN) announced positive preclinical data for SIL204, its RNA interference (RNAi) therapy, in human lung cancer cell lines with KRAS G12D mutations. The company also initiated a study on SIL204’s efficacy against a previously untested KRAS mutation, potentially broadening its application as a pan-KRAS treatment. Silexion is preparing for a Phase 2/3 clinical trial in Q2 2026, investigating SIL204 for KRAS-driven solid tumors, employing both intratumoral and systemic delivery.
This preclinical success is noteworthy because KRAS mutations are prevalent in various cancers, including a significant portion of lung cancer cases, a disease with limited treatment options and high incidence. SIL204’s potential to address a previously untested KRAS mutation could expand the therapeutic landscape considerably, offering new hope for patients with these challenging cancers. The advancement toward a Phase 2/3 trial demonstrates tangible progress in addressing a significant unmet medical need.
The study showed dose-dependent inhibition of lung cancer cells with the KRAS G12D mutation. This data validates Silexion’s lipid-conjugated delivery system, crucial for enhancing drug uptake into tumor cells, a known obstacle in siRNA technology for solid tumors. This delivery system could become a key differentiator for SIL204. Additionally, the company’s investigation of a new KRAS mutation could solidify SIL204’s position as a potential pan-KRAS treatment, targeting a wider range of these oncogenic drivers.
These results, coupled with previous positive findings in pancreatic and colorectal cancer models, reinforce SIL204’s potential as a versatile treatment option. The upcoming Phase 2/3 trial will be a pivotal step in determining the clinical efficacy and safety of SIL204. Positive outcomes could lead to a significant advancement in the treatment of KRAS-driven cancers, potentially transforming the standard of care for patients. The potential for pan-KRAS activity could further revolutionize how these cancers are treated, offering a more comprehensive approach compared to current therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
